Abstract
We evaluated the frequency of secondary amyloidosis, associated clinical features, and outcomes in ankylosing spondylitis (AS) patients diagnosed in the last decade. The medical records of AS patients diagnosed at single academic medical center were reviewed for clinical evidence of amyloidosis. During routine follow-up, routine urinalysis was performed at each visit; patients with significant proteinuria underwent rectal biopsy. We diagnosed 8 clinically apparent amyloidosis patients (1.1 %) in our cohort of 730 AS patients (508 males, 222 females). Four patients undergoing hemodialysis were diagnosed secondary amyloidosis. Three patients had nephrotic syndrome and renal dysfunction and one patient had non-nephrotic proteinuria. When AS patients with amyloidosis were compared to AS controls, it was observed that the amyloidosis group was older, had longer disease duration, higher initial BASDAI scores, and ESR values, and more frequent peripheral arthritis (p < 0.05). Logistic regression analysis revealed that the initial BASDAI level was an independent predictor for the development of secondary amyloidosis (OR:2.36). Six patients were administered anti-TNF therapy. The clinical findings resolved in these. In 2 patients with nephrotic syndrome and renal dysfunction, in addition to clinical improvement, there was a decrement in proteinuria; renal function improved or remained stable. Anti-TNF therapy is safe and effective in patients with renal failure, and at an earlier stage, appears effective in improving renal function. The development of proteinuria in AS patients should occasion a search for underlying amyloidosis.
Similar content being viewed by others
References
Senel S, Kisacik B, Ugan Y et al (2011) The efficacy and safety of etanercept in patients with rheumatoid arthritis and spondyloarthropathy on hemodialysis. Clin Rheumatol 30(10):1369–1372
Fernández-Nebro A, Olivé A, Castro MC et al (2010) Long-term TNF-alpha blockade in patients with amyloid A amyloidosis complicating rheumatic diseases. Am J Med 123(5):454–461
Gottenberg JE, Merle-Vincent F, Bentaberry F et al (2003) Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 48(7):2019–2024
van der Linden S, Valkenburg HA, Cats A et al (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368
Strobel ES, Fritshka E (1998) Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol 17:524–530
Gratacos J, Orellana C, Sanmarti R et al (1999) Secondary amyloidosis in ankylosing spondylitis. A systematic survey of 137 patients using abdominal fat aspiration. Rheumatology 24(5):912–915
Singh G, Kumari N, Aggarwal A et al (2007) Prevalence of subclinical amyloidosis in ankylosing spondylitis. J Rheumatol 34(2):371–373
Lehtinen K (1993) Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 52(3):174–176
Braun J, Pincus T (2002) Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 20(6 Suppl 28):S16–S22
Immonen K, Finne P, Hakala M et al (2008) No improvement in survival of patients with amyloidosis associated with inflammatory rheumatic diseases—data from the Finnish national registry for kidney diseases. J Rheumatol 35:1334–1338
Urieli-Shoval S, Linke RP, Matzner Y (2000) Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 7:64–69
Niewold TA, Gruys E, Arakawa T et al (1993) Recombinant human tumour necrosis factor-alpha (rhTNF-alpha)and rhTNF-alpha analogue enhance amyloid deposition in the Syrian hamster. Scand J Immunol 37:29–32
Tanaka N, Yonekura H, Yamagishi S et al (2000) The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-through nuclear factor-B, and by 17-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 33:25781–25790
Yan SD, Zhu H, Zhu A et al (2000) Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 6:643–651
Nakamura T, Higashi S, Tomoda K et al (2010) Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol 29(12):1395–1401
Acknowledgments
We do not have any financial support for this study.
Conflict of interest
There is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dönmez, S., Pamuk, Ö.N., Pamuk, G.E. et al. Secondary amyloidosis in ankylosing spondylitis. Rheumatol Int 33, 1725–1729 (2013). https://doi.org/10.1007/s00296-012-2646-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-012-2646-3